New England IRB (acquired by WCG IRB)
- Company typePrivate
- Founded-
- HeadquartersNot explicitly stated, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
New England IRB (acquired by WCG IRB) firmographics
Firmographics- Name
- New England IRB (acquired by WCG IRB)
- Legal name
- WCG Clinical
- Website
- https://neirb.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
New England IRB (acquired by WCG IRB) industry classification
Industry- Product category
- Institutional Review Board (IRB) Services
- NAICS
- Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Clinical Research Ethics & Human Subjects Protection Authorities (IRB/REC Oversight) (HLAJACAG)
- akta.pro secondary industry
- Research Administration & Compliance (Sponsored Programs, IRB/REB) (EDADAKAH)
Keywords
Where New England IRB (acquired by WCG IRB) is headquartered
LocationHeadquarters
- HQ city
- Not explicitly stated
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
New England IRB (acquired by WCG IRB) business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- IRB Review Services: WCG generates revenue through professional IRB (Institutional Review Board) review services for clinical trials. Revenue is derived from reviewing protocols and research documents for pharmaceutical companies, biotech startups, medical device companies, CROs, and academic institutions. Services include standard IRB review, IRB+ premium expedited service, and specialized reviews for Phase I, pediatric, biologics, social/behavioral research. The company operates 12 hours a day, 7 days a week processing reviews.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Standard IRB Review |
| Subscription | Multi-year contract | IRB+ Premium Service |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels8 records
New England IRB (acquired by WCG IRB) product offering
Product offeringCore offering
WCG IRB provides independent ethical review services for clinical research protocols on behalf of pharmaceutical companies, biotech startups, medical device companies, CROs, and academic institutions. A board of nearly 200 IRB experts, augmented by an expert clinical advisory network, processes reviews 12 hours a day, 7 days per week, delivering new protocol determinations in less than 6 days and new site determinations in less than 2 days. The offering is supported by the ClinSphere® technology platform integrating eReview Manager, IRBNet, InvestigatorSpace®, AIMS®, Total Enrollment, Total Feasibility, eResearch Enterprise CTMS, CTLS, ClinSphere Trial IntelX™, and Latitude.
Product overview
WCG IRB operates as a unified platform-plus-modules architecture centered on its core IRB Review service. The primary platform, ClinSphere®, integrates multiple technology solutions including eReview Manager, IRBNet, InvestigatorSpace®, AIMS®, Total Enrollment, Total Feasibility, eResearch Enterprise CTMS, Clinical Trial Listing Service (CTLS), ClinSphere Trial IntelX™, and Latitude. Premium service tiers include IRB+ for accelerated processing and specialized review services for pharmaceuticals, medical devices, biologics, Phase I trials, pediatrics, and social/behavioral research. Additional offerings include IBC Review, Endpoint Adjudication Committee, Data Monitoring Committees, WCG Site Network, Total Training, and Safety Letter Distribution.
Differentiator
Problem solved
Functional benefit
Brands
- IRB+: Streamlined ethical review service for accelerated processing and white-glove service
- ClinSphere eReview Manager
Products and services
- WCG IRB Review Independent central IRB ethical review service for clinical research protocols across all study phases and therapeutic areas, for sponsors, CROs, medical device companies, biotech startups, and academic institutions.
- IBC Review Independent Institutional Biosafety Committee review for clinical studies involving biologics, cell therapy, gene therapy, stem cells, viral vectors, and gene transfer protocols.
- Endpoint Adjudication Committee Independent committee service that evaluates and adjudicates clinical trial endpoints for sponsors requiring unbiased endpoint assessment.
- Data Monitoring Committees Independent Data (Safety) Monitoring Committee service that oversees clinical trial data and ensures participant safety throughout the study.
- Total Training Clinical trial training solutions for research site staff and investigative personnel to support compliance and protocol adherence.
- Safety Letter Distribution Distribution service for safety communications from sponsors to clinical trial sites and investigators.
- WCG Site Network Network of clinical research sites used by sponsors and CROs to accelerate site onboarding and study activation.
- ClinSphere® Unified technology platform that integrates WCG's clinical research solutions, including IRB review, site network management, and analytics tools.
- eReview Manager Online platform for submitting studies to WCG IRB, tracking reviews, and managing IRB documentation in real time.
- IRBNet Technology platform for IRB document management and submission tracking.
- InvestigatorSpace® Training & Safety Portal Training and safety communication portal for clinical research investigators.
- AIMS® Analytics and information management system for clinical research data.
- Total Enrollment Participant recruitment and enrollment technology solution for clinical trials.
- Total Feasibility Study feasibility assessment technology for evaluating site capabilities and study requirements.
- eResearch Enterprise CTMS Clinical trial management system for study operations and oversight.
- Clinical Trial Listing Service (CTLS) Service for listing and managing clinical trial information.
- ClinSphere Trial IntelX™ Trial intelligence and analytics solution for clinical research benchmarking and performance management.
- Latitude Platform for clinical research site management and collaboration.
- Recruitment & Retention Solutions to help sponsors overcome barriers and reach study enrollment goals faster through targeted recruitment and retention services.
- Benchmarking & Performance Management Benchmarking and performance management solutions for clinical research organizations.
- Quality & Compliance Quality and compliance advisory and program support for clinical research organizations.
- Statistical Consulting Statistical consulting solutions for clinical research data analysis and trial design.
- Diversity, Equity, & Inclusion Solutions supporting diversity, equity, and inclusion across clinical research programs.
- Trial Design & Protocol Planning Trial design and protocol planning consulting service to help sponsors structure clinical research programs.
- Study Planning & Review Service to design protocols to protect participants and minimize risk prior to IRB submission.
- Therapeutic Area Solutions Specialized IRB review and clinical research support across therapeutic areas including Hematology/Oncology, CNS, Cardiovascular, Metabolic, Infectious Disease, Dermatology, Immunology, and Gastroenterology.
Quantifiable outcome
- Less than 6 days for new protocol determinations
- +2 more outcomes
Companies that use New England IRB (acquired by WCG IRB)
Customer profileNamed customers3 records
Segments7 records
Ideal customer profiles5 records
New England IRB (acquired by WCG IRB) technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
New England IRB (acquired by WCG IRB) partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Dr. Vince Clinical ResearchcoreWCG IRB expanded Phase I review services through partnership with Dr. Vince Clinical Research, enhancing capabilities for first-in-human studies. This partnership brings additional expertise in Phase I clinical trial review, with board members who are former Phase I investigators whose experience is invaluable for residential studies and complex pharmacology trials.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
New England IRB (acquired by WCG IRB) competitors and assessment
Company assessmentBroad incumbents
- Parexel: Parexel (including PPD) is a global CRO serving pharma and biotech sponsors across clinical operations, regulatory, and site services. It is also a named WCG customer, illustrating how CRO incumbents both partner and compete in adjacent IRB-adjacent workflows.
- IQVIA: IQVIA is a global CRO and clinical research services incumbent offering protocol operations, site management, and regulatory/ethics coordination at scale. While not a pure IRB, it competes for sponsor budgets and increasingly bundles IRB-adjacent capabilities.
- Labcorp Drug Development (Fortrea): Fortrea, spun out from Labcorp, is a global clinical development and commercialization services incumbent. It competes for sponsor R&D budgets and provides overlapping clinical operations and central lab capabilities relevant to WCG's broader platform.
- Syneos Health: Syneos Health is a fully integrated biopharmaceutical solutions organization offering clinical and commercial services across development, site, and recruitment. It is comparable to the broader WCG platform footprint beyond pure IRB review.
- ICON plc: ICON is a global CRO offering clinical research, site activation, and central laboratory services to pharma and biotech sponsors. It overlaps with WCG's ClinSphere-enabling services (site, recruitment, feasibility) as part of a broader portfolio.
- Charles River Laboratories: Charles River is an established preclinical and clinical services incumbent serving pharma and biotech sponsors across discovery, safety, and clinical trial support. It overlaps with WCG in clinical operations and broader sponsor services.
Direct peers
- Advarra: Advarra is a leading central IRB formed from the merger of Schulman IRB and Quorum Review, offering IRB, IBC, and HRPP services to sponsors, CROs, and academic institutions. It is the most direct head-to-head competitor to WCG IRB across enterprise review and oncology/genetics protocols.
- Sterling IRB: Sterling IRB is an AAHRPP-accredited central IRB serving academic, pharmaceutical, and CRO sponsors with protocol review and study management services. It competes directly with WCG on turnaround time, expertise, and accreditation.
- BRANY: Biomedical Research Alliance of New York (BRANY) provides IRB and HRPP services with strong academic medical center roots, including the Icahn School of Medicine at Mount Sinai. It is a directly comparable central IRB serving sponsors and academic institutions.
- Copernicus Group IRB: Copernicus Group IRB (CGI) is an AAHRPP-accredited central IRB providing independent ethical review for clinical research across pharmaceutical, biotech, and medical device sponsors. It is a direct alternative for sponsor review work.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
New England IRB (acquired by WCG IRB) social profiles
Digital presenceNew England IRB (acquired by WCG IRB) compliance and trust
Trust signalCompliance10 records
New England IRB (acquired by WCG IRB) financial estimates
Financial estimateRevenue estimate
Valuation estimate
New England IRB (acquired by WCG IRB) leadership team
Management profileNumber of profiles
New England IRB (acquired by WCG IRB) funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
New England IRB (acquired by WCG IRB) M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about New England IRB (acquired by WCG IRB)
What does New England IRB (acquired by WCG IRB) do?
WCG IRB provides independent ethical review services for clinical research protocols on behalf of pharmaceutical companies, biotech startups, medical device companies, CROs, and academic institutions. A board of nearly 200 IRB experts, augmented by an expert clinical advisory network, processes reviews 12 hours a day, 7 days per week, delivering new protocol determinations in less than 6 days and new site determinations in less than 2 days. The offering is supported by the ClinSphere® technology platform integrating eReview Manager, IRBNet, InvestigatorSpace®, AIMS®, Total Enrollment, Total Feasibility, eResearch Enterprise CTMS, CTLS, ClinSphere Trial IntelX™, and Latitude.
Is New England IRB (acquired by WCG IRB) a public or private company?
New England IRB (acquired by WCG IRB) is a private company. It is classified as unknown and is currently operating.
When was New England IRB (acquired by WCG IRB) founded?
New England IRB (acquired by WCG IRB) was founded in -1. It employs 1 to 10 people.
Where is New England IRB (acquired by WCG IRB) based?
New England IRB (acquired by WCG IRB) is headquartered in Not explicitly stated, United States, in the North America region.
How does New England IRB (acquired by WCG IRB) make money?
One revenue line is on record: IRB Review Services.
Who are New England IRB (acquired by WCG IRB)'s main competitors?
Broad incumbents on record are Parexel, IQVIA, Labcorp Drug Development (Fortrea), Syneos Health, ICON plc and Charles River Laboratories. Direct peers are Advarra, Sterling IRB, BRANY and Copernicus Group IRB.
Does New England IRB (acquired by WCG IRB) have an API?
No public API is recorded for New England IRB (acquired by WCG IRB).
What industry is New England IRB (acquired by WCG IRB) in?
New England IRB (acquired by WCG IRB)'s product category is Institutional Review Board (IRB) Services. Its primary akta.pro industry code is HLAJACAG, Clinical Research Ethics & Human Subjects Protection Authorities (IRB/REC Oversight), with a secondary code of EDADAKAH, Research Administration & Compliance (Sponsored Programs, IRB/REB). Its NAICS code is 54169 and its SIC code is 8090.